Efficacy of Dihydroartemisinin for Treating Acne Vulgaris
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: dihydroartemisinin.
- Who it may be relevant to
- Registry conditions: Acne Vulgaris. Basic parameters: 18 years — 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Acne Vulgaris
Overview
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is: • Does DHA improve the acne severity by at least one grade after treatment. Researchers will treat patients who are clinically diagnosed as Acne Vulgaris to see if DHA works to alleviate the symptoms of Acne Vulgaris. Participants will: * Take DHA every day for 3 months * Visit the clinic once every month for checkups and tests
Interventions
- Drug dihydroartemisinin
DHA 40mg tid for 90 days
Primary outcome measures
- Improvement of acne severity by Investigator's Global Assessment (IGA) [Time frame: Before and immediately after 90-day treatment]
Secondary outcome measures (5)
- Change of Global Acne Grading System (GAGS) score from baseline to the end of treatment [Time frame: Before and immediately after 90-day treatment]
- Change of inflammatory lesion count from baseline to the end of treatment [Time frame: Before and immediately after 90-day treatment]
- Change of non-inflammatory lesion count from baseline to the end of treatment [Time frame: Before and immediately after 90-day treatment]
- Number of participants who achieved an IGA score of 0 or 1 at the end of treatment [Time frame: Before and immediately after 90-day treatment]
- Change of serum total testosterone from baseline to the end of treatment [Time frame: Before and immediately after 90-day treatment]
Eligibility criteria
Inclusion criteria
- Clinically diagnosed with acne vulgaris;
- For female patients, no pregnancy plans within the next 6 months.
Exclusion criteria
- Patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months;
- Patients who have used topical medications for acne within the past 2 weeks;
- Pregnant or breastfeeding women;
- Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Zhongshan Hospital Fudan University — Shanghai
Identifiers
NCT: NCT07007078 · B2025-113R